CB 3717

Also Known As:

5,8-dideaza-N(10)propargylfolic acid; CB-3717; CB3717; ICI 155387; ICI-155387; N(10)-propargyl-5,8-dideazafolate; N-(4-(N-((2-amino-3,4-dihydro-4-oxo-6-quinazolinyl)methyl)-N-prop-2-ynylamino)benzoyl)glutamic acid; NSC 327182; NSC-327182; PDDF; n-(4(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-L-glutamic acid

Networked: 37 relevant articles (2 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - CB 3717: 37
    - Pteridines: 147
      - Pterins: 160
        Folic Acid: 19425
        CB 3717: 37

Experts

1.	Berciano, Maria T: 1 article (04/2016)
2.	Casafont, Iñigo: 1 article (04/2016)
3.	Lafarga, Miguel: 1 article (04/2016)
4.	Mata-Garrido, Jorge: 1 article (04/2016)
5.	Tapia, Olga: 1 article (04/2016)
6.	Bonanni, Laura: 1 article (06/2010)
7.	Monaco, Daniela: 1 article (06/2010)
8.	Onofrj, Marco: 1 article (06/2010)
9.	Perfetti, Bernardo: 1 article (06/2010)
10.	Thomas, Astrid: 1 article (06/2010)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 06/01/1988 - "Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer." 08/01/1988 - "The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid)."
2.	T-Cell Leukemia (Leukemia, T Cell) 09/01/1997 - "TMQ was more potent against approximately 200-fold N10-propargyl-5,8-dideazafolic-acid (CB3717)-resistant human T-cell leukemia MOLT-3 sublines developed in PGA (MOLT-3/CB3717(200)-PGA) or leucovorin (MOLT-3/CB3717(200)-LV), as compared to the parent cells; MOLT-3/CB3717(200)-PGA and MOLT-3/CB3717(200)-LV cells were resistant to CB3717 by virtue of impaired transport, only the former possessing gene amplification of thymidylate synthase. "
3.	Hepatocellular Carcinoma (Hepatoma) 06/01/1989 - "Transport studies in vitro established that DMPDDF effectively inhibits MTX influx into H35 hepatoma cells, whereas PDDF has no effect on MTX transport in this cell line. " 06/01/1987 - "Our results suggest that CB3717 will be a useful new therapeutic agent in hepatocellular carcinoma. " 03/01/1986 - "These results suggest that CB3717 may be a useful new therapeutic agent in human primary liver cell carcinoma and that blocking the salvage pathway may further increase efficacy." 01/01/1986 - "Four patients with primary hepatocellular carcinoma were treated with CB3717, and serial changes in the serum AFP characteristics were examined. " 06/01/1987 - "In a Phase II clinical trial, 14 consecutive, unselected patients with primary hepatocellular carcinoma were treated with a new inhibitor of thymidylate synthase, CB3717. "
4.	Breast Neoplasms (Breast Cancer) 01/01/1987 - "In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma. " 04/01/1988 - "Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer." 04/01/1988 - "Fifty-two patients with progressive advanced breast cancer were treated with the novel antifolate CB 3717 (N10-propargyl-5,8-dideazofolic acid) which inhibits thymidylate synthetase. "
5.	Leukemia 01/01/1996 - "In this study, effects of reduced and oxidized folates on the development of resistance to a thymidylate synthase (TS) inhibitor, N10-propargyl-5, 8-dideazafolic acid (CB3717), were examined in the human leukemia cell line MOLT-3. " 10/01/1992 - "N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate." 01/01/1991 - "A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717)." 01/01/1989 - "The findings suggest that the depletion of intracellular thymine nucleotide levels by the antifolates, MTX, TMQ, and CB-3717 is the primary event involved in the maturation of HL-60 leukemia cells produced by these agents and that maturation occurs concomitantly with a high level of cytotoxicity.(ABSTRACT TRUNCATED AT 250 WORDS)" 01/01/1993 - "In order to clarify a molecular mechanism of folate resistance in leukemia cells, we studied alterations of the dihydrofolate reductase (DHFR) gene in a human leukemia cell line, MOLT-3, and its sublines made resistant to methotrexate (MTX), trimetrexate (TMQ) and N10-propargyl-5,8-dideazafolic acid (CB3717), alone or in combination. "

Related Drugs and Biologics

1.	Thymidylate Synthase
2.	Prostaglandins A
3.	Fluorouracil (Carac)
4.	Leucovorin (Folinic Acid)
5.	Folic Acid Antagonists
6.	Acids
7.	Trimetrexate (JB11)
8.	Methotrexate (Mexate)
9.	Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
10.	Hydroxymethyl and Formyl Transferases

Related Therapies and Procedures

1.	Remission Induction